Treatment Selection for Patients With NSCLC With High PD-L1 Expression

Released On
Feburary 4, 2021

Expires On
Feburary 4, 2022

Media Type
Internet

Completion Time
30 minutes

Specialty
Primary Care

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC.
 

This activity is supported by an educational grant from Bristol-Myers Squibb Company and Merck & Co, Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals (HCPs) who manage patients with non-small cell lung cancer (NSCLC).

Program Overview

The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy. In addition, several more ICI-based regimens are currently under US Food and Drug Administration (FDA) review and are expected to be added to the armamentarium in the near future. Although these multiple first-line regimens provide oncology clinicians and their patients with options to select from, this also creates a major challenge: Remaining up to date on the latest clinical trial data for existing and emerging ICI-based regimens, as well as applying these changes to improve treatment selection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the latest clinical trial data on immunotherapy-based combination regimens for the first-line treatment of NSCLC.
  • Select evidence-based first-line therapy for patients with advanced NSCLC, while considering patient- and treatment-related characteristics.

Agenda

  • Introduction to NSCLC treatment
  • Current and pending FDA approvals for the first-line treatment of NSCLC
  • Case: Patient with newly diagnosed NSCLC with high PD-L1 expression
    • Update on clinical trial data
    • Treatment selection
    • Management of irAEs
  • Conclusion and faculty panel discussion

Faculty

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Cancer
Los Angeles, CA

Matthew D. Hellmann, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 0.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Matthew D. Hellmann, MD

  • Royalty: AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company
  • Consulting Fees: Achilles; Arcus; AstraZeneca; Blueprint Medicines Corporation; Bristol-Myers Squibb Company; Genentech, Inc; Immuna; Merck & Co, Inc; Mirati; Nektar; Shattuck Labs, Inc; Syndax
  • Grant/Research Support: Bristol-Myers Squibb Company
  • Stock Shareholder: Arcus; Immunai; Shattuck Labs, Inc

Karen Reckamp, MD, MS

  • Consulting Fees: Amgen Inc; AstraZeneca; Blueprint Medicines Corporation; Calithera Biosciences, Inc; Daiichi Sankyo, Inc; Eli Lilly and Company; Euclises Pharmaceuticals, Inc; Genentech, Inc.; Guardant Health Janssen Pharmaceuticals, Inc; KGA; Merck & Co, Inc; Precision Health; Takeda Pharmaceutical Company Ltd; Tesaro
  • Grant/Research Support: AbbVie Inc; ACEA Biosciences; Adaptimmune; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; Cedars Sinai; Calithera Biosciences, Inc.; Genentech, Inc.; GlaxoSmithKline; Guardant Health; Janssen Pharmaceuticals, Inc; Loxo Oncology; Molecular Partners; Seattle Genetics; Spectrum Pharmaceutical, Inc.; Takeda Pharmaceutical Company Ltd; Xcovery; Zenopharm

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Instructions for Participation and Credit

To receive a CME certificate of participation, you should:

  1. Follow instructions to register or log in with your professional information and complete the preactivity assessment
  2. View the online activity in its entirety
  3. Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.

Course Viewing Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: https://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Contact Information

If you have any questions or comments, please email us at contactus@paradigmmc.com.